Zydus Cadila’s Corona Medicine Virafine has been approved for emergency use.
The pharmaceutical company Zydus Cadila claims that its corona drug Virafin reduces the need for oxygen support in patients (Reduce Oxygen Support Requirement). The company has started dispatching its medicine.
New Delhi. Millions of new cases of Corona virus are coming in the country every day (Coronavirus Cases in India). Meanwhile, scientists and experts from all over the world are making new medicines (Covid-19 Medicines) to deal with it. Work is still underway on several Coronavirus Vaccine. In this series, the corona medicine ‘Virafin’ of pharmaceuticals company Zydus Cadila has been approved for emergency use in moderate cases of corona infection. Now Zydus Cadila has fixed the price of this drug. The pharma company claims that its Kovid-19 medicine reduces the need for oxygen support during treatment. DGCI approved the use of single-use therapy The country’s drug regulator Drug Controller General of India (DGCI) has approved the use of Corona Medicine Virafin as a single use therapy on 23 April 2021. Zydus Cadila has fixed the price of one dose of Virafin at Rs 11,995. The company has started supplying Virafin. The company claims that Virafin can be used in moderate cases of infection. Explain that when the viral load in the infected person is between moderate and high, then the need for oxygen support increases rapidly. The company has claimed that the use of Virafin will reduce the viral load in the patient and the need for oxygen support will decrease (Reduces Oxygen Support Requirement). read this also- Gold Price Today: Gold fell after several days of fast, Silver came down below 71 thousand, see new prices quicklyPatients with moderate viral load recover from 7th dose on 7th day Managing Director of Cadila Healthcare Limited, Dr. Sherville Patel said that if given at the right time to Virafin, it drastically reduces the viral load. This medicine has come at a time when people are feeling the need of it. We will continue to provide this medicine to the people in the fight against Corona. Zydus Cadila has claimed that 91.15 percent of corona patients were negative in the RT-PCR test on the 7th day of treatment with PegIFN. The company said that in the Phase III trial, most patients with moderate viral load had fully recovered on the 7th day of giving a dose. Based on the results of this trial, DCGI has approved its emergency use.